-
Bangladesh Test cricket reboot delivers in style with historic win
-
Ukraine badminton star: 'How can you feel normal when bombs are falling?'
-
Virgin moves closer to launching Eurostar rival in 2030
-
Rain brings respite as Belgium wrestles massive wildfire
-
Indian marble waste dump becomes unlikely tourist attraction
-
Most stocks rise as US data ease rate fears but fuel economic worries
-
Coach says Australia 'let standards slip' in shock Bangladesh loss
-
India take control of Galle Test as Sri Lanka slump to 99-5
-
Hawaii recovery efforts begin as Lala downgraded, moves west
-
Australia's mushroom murderer appeals conviction
-
Food safety crackdown snares Mumbai's famed restaurants
-
The Nigerian fishing community being eaten up by the Atlantic
-
Trump says US scaling back military drills with Seoul hours before start
-
Kushner to meet Netanyahu after talks with Hamas on Gaza plan
-
Nearly 13,000 displaced after deadly Indonesian quake
-
Photos, memories all that remain for Colombia's bereaved after quake
-
Axe hangs over Australian batters after Darwin 'disaster'
-
Sabalenka squeezes out win on sixth match point in Cincinnati
-
Is this cave in Turkey where Homer wrote 'The Odyssey'?
-
Trump says US scaling back military drills with South Korea hours before start
-
Winning back walls from gangs, artists fill El Salvador's towns with color
-
Jason Arday: UK academic who died amid plagiarism storm
-
Opening arguments expected in Tupac murder trial
-
Sabbath cafe clash lays bare Israel faultlines
-
As machinery removes rubble, hopes for survivors from Colombian quake dwindle
-
SEG Announces 2026 Interim Results
-
Caledonia Mining Corporation Plc: Director Shareholding Notification
-
HM Exploration Commences Borehole & Surface EM Surveys at Lewis Pilley's
-
First Class Metals PLC Announces Application for OTCID Quotation
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 17
-
Gold Roth IRA: How It Works, Rules, Taxes, Fees, and What Investors Should Know in 2026 (Guide Released)
-
Top-ranked Scheffler powers to PGA St. Jude Championship victory
-
Trump says US scaling back military drills with South Korea
-
Jacquet scores on Liverpool debut in friendly win over Como
-
Zambia's Hichilema takes early lead in reelection bid
-
Hawaii's Big Island begins recovery efforts as Hurricane Lala downgrades, moves west
-
Sabalenka squeezes out a win on sixth match point in Cincinnati
-
Spidey swings high for third weekend in N. American box office
-
Duplantis dominant, Hunt hits four and Asher-Smith makes history
-
Eagle and late birdie lift Jeeno to LPGA Portland Classic win
-
Spanish soldier dies in Aragon wildfire
-
Duplantis masterclass for fourth Euro pole vault title
-
PSG beaten by Lens in French Champions' Trophy
-
Records for Asher-Smith, Hunt as Britain win 4x100m mixed relay
-
Rybakina, Andreeva race into Cincinnati third round
-
Barcelona reach deal with Man City to sign Rodri
-
Amy Hunt bags fourth Euro gold as Britain win 4x100m mixed relay
-
Misery for Maresca as Man City make dismal start to life after Guardiola
-
Spanish soldier dies in Aragon wildfire: regional leader
-
Strikes kill 19 in Russia and Ukraine
US panel recommends nonprescription use of contraception pill
A US panel of health experts voted Wednesday in favor of making birth control pills available without a prescription, a move backed by reproductive rights advocates especially in the wake of a Supreme Court ruling overturning the national right to abortion.
The independent panel voted unanimously that the benefits of allowing the medicine, Opill, to be sold over the counter, outweighed the risks and would reduce hurdles associated with visiting a doctor that impact lower income groups disproportionately.
"I believe that the efficacy and safety of this birth control form was established over half a century ago," said panelist Jolie Haun of the James A. Haley Veterans' Hospital.
"We now have been presented with ample data demonstrating the effective safe use and benefits for people who want to have access to reproductive autonomy."
The committee's votes are usually accepted by the Food and Drug Administration, which means the pill, which is made by HRA Pharma, might be available without prescription in the coming weeks.
While likely, approval is not assured. FDA scientists highlighted safety concerns, such as the potential impact on people with a history or current diagnosis of breast cancer, or whether they would understand the pill needs to be taken the same time every day to prevent pregnancy.
"There is also concern that some consumers may not consistently use the product correctly on a chronic basis and be at risk for pregnancy, but not recognize that they are pregnant because of the irregular bleeding that would be ascribed to the known side effect," the FDA wrote in a document.
The push for a non-prescription pill has taken on new urgency in light of a Supreme Court decision overturning the constitutional right to abortion, leading to numerous bans and severe restrictions in conservative states.
It has received support from health groups such as the American Medical Association and American College of Obstetricians and Gynecologists.
If the pill is approved, the US would join more than 100 other countries where the pill is available without a prescription, including the UK which requires a consultation with a pharmacist.
Opill is known as a "mini pill" because it contains progestin only.
Another company, Cadence, is in talks with the FDA about making its combination pill, which contains both estrogen and progestin, available over the counter.
P.Martin--AMWN